top of page
  • Active, not recruiting

NCT03631043: Phase 1 - Personalized Vaccine in Treating Participants With Smoldering MM

Updated: Feb 10

  • Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

Personalized Vaccine Myeloma

This early phase I trial studies the side effects of personalized vaccine in treating participants with smoldering multiple myeloma. Vaccines made from a person's blood and bone marrow may help the body build an effective immune response to kill cancer cells.

Sponsor Identifier: NCT03631043

Official Title: A Personalized Vaccine for the Immune Prevention of Multiple Myeloma

First Posted : August 15, 2018

Click here for details on


Procedure: Biopsy Specimen Radiography

Drug: Lenalidomide

Biological: Vaccine Therapy


- Texas: The University of Texas MD Anderson Cancer Center Houston



United States, Texas

Posts Archive
bottom of page